No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab.
Magnus JohnssonHelen H FarmanKaj BlennowHenrik ZetterbergClas MalmeströmMarkus AxelssonJan N LyckePublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2022)
We concluded that extending the NZ dosing interval did not increase axonal damage, as determined with sNfL, in patients with RRMS.